Global Fecal Occult Testing market 2016-2020

  • ID: 3844068
  • Report
  • Region: Global
  • 89 pages
  • TechNavio
1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • ASAN PHARM
  • BIOHIT Healthcare
  • Epigenomics
  • NanoRepro AG
  • Quest Diagnostics
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

About Fecal Occult Testing

Fecal occult testing is simple and non-invasive in nature, thereby increasing its preference among many physicians. The results of few of the fecal occult tests can be obtained rapidly through point-of-care (POC) test kits such as Alere's Clearview iFOB, and Beckman Coulter's Hemoccult II SENSA. For instance, the Clearview iFOB test is based on human hemoglobin and gastrointestinal bleeding, and can provide results in five minutes. Beckman Coulter's Hemoccult II SENSA slides allow people to collect fecal samples at home settings and send them to hospitals, laboratories, and diagnostic centers.

The analysts forecast the global fecal occult testing market to grow at a CAGR of 4.82% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global fecal occult testing market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of fecal occult testing products used to perform colorectal cancer screening.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Fecal Occult Testing Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Beckman Coulter
- Eiken Chemical
- Epigenomics
- Quidel

Other prominent vendors
- Abbott Laboratories
- AccuBioTech
- Applied Proteomics
- ASAN PHARM.
- Assure Tech.
- BIOHIT Healthcare
- EDP Biotech
- FUJIREBIO
- GeneNews
- NanoRepro
- Nantong Egens Biotechnology
- Orion Diagnostica
- Polymedco
- Quest Diagnostics
- Randox
- VolitionRx

Market drivers
- Government initiatives and pilot programs worldwide
- For a full, detailed list, view the full report

Market challenges
- High cost of FITs and limited reimbursement
- For a full, detailed list, view the full report

Market trends
- Direct-to-consumer laboratory testing
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • ASAN PHARM
  • BIOHIT Healthcare
  • Epigenomics
  • NanoRepro AG
  • Quest Diagnostics
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market Overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 06: Market segmentation by product
  • Global fecal occult testing market by FIT
  • Global fecal occult testing market by guaiac test
  • Global fecal occult testing market by stool DNA test
PART 07: Market segmentation by end-user
  • Global fecal occult testing market by hospitals
  • Global fecal occult testing market by clinical diagnostic laboratories
  • Global fecal occult testing market by physicians' office laboratories
PART 08: Geographical segmentation
  • Fecal occult testing market in Americas
  • Fecal occult testing market in EMEA
  • Fecal occult testing market in APAC
PART 09: Market drivers
  • Rise in geriatric population
  • Government initiatives and pilot programs worldwide
  • Shift toward patient-centered model (POC FITs) for home use
PART 10: Impact of drivers

PART 11: Market challenges
  • High cost of FITs and limited reimbursement
  • Inaccuracies in diagnosis
  • Limited awareness and reluctance of physicians to recommend fecal occult testing
PART 12: Impact of drivers and challenges

PART 13: Market trends
  • Collaboration between research centers and manufacturers
  • Online marketing of fecal occult immunological test devices
  • Direct-to-consumer laboratory testing
PART 14: Vendor landscape
  • Competitive scenario
PART 15: Key vendor analysis
  • Geographical presence: Major vendors
  • Beckman Coulter
  • Eiken Chemical
  • Epigenomics
  • Quidel
  • Key news
  • Other prominent vendors
PART 16: Appendix
  • List of abbreviations
PART 17: About the Author

List of Exhibits
Exhibit 01: Global fecal occult testing market: Three significant estimations
Exhibit 02: Product offerings
Exhibit 03: Colorectal cancer screening tests: Advantages and disadvantages of fecal occult testing
Exhibit 04: Scale of colorectal cancer cases in UK
Exhibit 05: Adoption of Cologuard in US 2014-2015
Exhibit 06: Segmentation of global fecal occult testing market
Exhibit 07: Global fecal occult testing market: Impact assessment
Exhibit 08: Global fecal occult testing market 2015-2020 ($ millions)
Exhibit 09: New cases and deaths related to colorectal cancer per 100,000 people in US 2004-2014
Exhibit 10: Government guidelines and support in some developed countries
Exhibit 11: Five forces analysis
Exhibit 12: Global fecal occult testing market by product 2015 and 2020
Exhibit 13: Global fecal occult testing market by FIT: An overview
Exhibit 14: Global fecal occult testing market by FIT 2015-2020 ($ millions)
Exhibit 15: Comparison of FIT and guaiac test
Exhibit 16: Global fecal occult testing market by guaiac test: An overview
Exhibit 17: Global fecal occult testing market by guaiac test 2015-2020 ($ millions)
Exhibit 18: Global fecal occult testing market by stool DNA test: An overview
Exhibit 19: Global fecal occult testing market by stool DNA test 2015-2020 ($ millions)
Exhibit 20: Global fecal occult testing market segmentation by end-user 2015
Exhibit 21: Revenue generated by diagnostic and medical laboratories in US 2009-2014
Exhibit 22: Global fecal occult testing market segmentation by geography 2015 and 2020
Exhibit 23: Fecal occult testing market in Americas: An overview
Exhibit 24: Fecal occult testing market in Americas 2015-2020 ($ millions)
Exhibit 25: Fecal occult testing market in Americas: Metrics analysis for various countries 2015 and 2020
Exhibit 26: Fecal occult testing market in US: Key takeaways
Exhibit 27: Fecal occult testing market in EMEA: An overview
Exhibit 28: Colorectal cancer mortality per 100,000 individuals in European countries 2003 and 2013
Exhibit 29: Fecal occult testing market in EMEA 2015-2020 ($ millions)
Exhibit 30: Fecal occult testing market in EMEA: Metrics analysis of various countries 2015 and 2020
Exhibit 31: Fecal occult testing market in UK: Key takeaways
Exhibit 32: Fecal occult testing market in APAC: An overview
Exhibit 33: Colorectal cancer mortality per 100,000 individuals in APAC 2003 and 2013
Exhibit 34: Fecal occult testing market in APAC 2015-2020 ($ millions)
Exhibit 35: Fecal occult testing market in APAC: Metrics analysis for various countries 2015 and 2020
Exhibit 36: People in age group 60 years and above worldwide 2010-2050
Exhibit 37: Government initiatives for colorectal cancer and fecal occult testing in some countries
Exhibit 38: Some POC FITs available in market
Exhibit 39: Impact of drivers
Exhibit 40: Study results: Potential barriers affecting adoption of FOBTs
Exhibit 41: Impact of drivers and challenges
Exhibit 42: Some collaborations and their impact
Exhibit 43: Some companies and their distribution
PARTners
Exhibit 44: Global fecal occult testing market: Competitive structure analysis 2015
Exhibit 45: Global fecal occult testing market: Competitive landscape analysis
Exhibit 46: Market penetration of vendors of fecal occult testing kits 2015
Exhibit 47: Global fecal occult testing market: Strategic success factors of companies
Exhibit 48: Major vendors: Regional analysis
Exhibit 49: Beckman Coulter: Profile summary
Exhibit 50: Beckman Coulter: Strength analysis
Exhibit 51: Beckman Coulter: Growth strategy matrix
Exhibit 52: Beckman Coulter: Opportunity assessment
Exhibit 53: Eiken Chemical: Profile summary
Exhibit 54: Eiken Chemical: Strength analysis
Exhibit 55: Eiken Chemical: Growth strategy matrix
Exhibit 56: Eiken Chemical: Opportunity assessment
Exhibit 57: Epigenomics: Profile summary
Exhibit 58: Epigenomics: Strength analysis
Exhibit 59: Epigenomics: Growth strategy matrix
Exhibit 60: Epigenomics: Opportunity assessment
Exhibit 61: Quidel: Profile summary
Exhibit 62: Quidel: Strength analysis
Exhibit 63: Quidel: Growth strategy matrix
Exhibit 64: Quidel: Opportunity assessment
Exhibit 65: Other prominent vendors
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • ASAN PHARM
  • BIOHIT Healthcare
  • Epigenomics
  • NanoRepro AG
  • Quest Diagnostics
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

New Report Released: – Global Fecal Occult Testing Market 2016-2020

The author of the report recognizes the following companies as the key players in the global fecal occult testing market: Beckman Coulter, Eiken Chemical, Epigenomics, and Quidel.

Other Prominent Vendors in the market are: Abbott Laboratories, AccuBioTech, Applied Proteomics, ASAN PHARM, Assure Tech. (Hangzhou), BIOHIT Healthcare, EDP Biotech, FUJIREBIO, GeneNews, NanoRepro AG, Nantong Egens Biotechnology, Orion Diagnostica, Polymedco, Quest Diagnostics, Randox, and VolitionRx.

Commenting on the report, an analyst from the research team said: “Direct-to-consumer laboratory testing is an important trend spurring this market’s growth prospects. Direct-to-consumer laboratory testing allows people to receive test kits and send samples to laboratories. Many people in the age group 60 years and above in developed countries such as Australia, the US, the UK, and Germany opt for direct-to-consumer genetic testing. These products can be selected online services and can be accessed from any geographical location. The cost of these products is less compared with traditional genetic testing kits. Direct-to-consumer genetic testing kits cost $100-$1,200. Companies or laboratories such as Color Genomics in the US and Mapmygenome in India offer direct-to-consumer genetic testing services that help identify or screen for colorectal cancer.”

According to the report, shift toward patient-centered model (POC FITs) for home use is one of the ley drivers contributing to the growth of this market. Various government and non-government initiatives have helped increase awareness and research data about colorectal cancer. This presents significant opportunities for improving cancer management. Devices used for testing at or near the site of the patient are known as POC devices. These devices can be used at home settings; however, people need to consult their physicians for further disease diagnosis and treatment. These devices can also be used outside a laboratory and in hospitals and clinics.

Further, the report states that limited awareness and reluctance of physicians to recommend fecal occult testing is a major challenge this market is facing. Awareness about colorectal cancer and associated screening methods among people is limited. Moreover, people who are aware of screening methods mostly opt for colonoscopy; a significant number of physicians worldwide are of the opinion that colonoscopy can help reduce the mortality rate associated with colorectal cancer. The lack of efficacy in test results of fecal occult testing similar to guaiac-based tests and FITs encourages physicians to recommend colonoscopy.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

- Beckman Coulter
- Eiken Chemical
- Epigenomics
- Quidel
- Abbott Laboratories
- AccuBioTech
- Applied Proteomics
- ASAN PHARM
- Assure Tech. (Hangzhou)
- BIOHIT Healthcare
- EDP Biotech
- FUJIREBIO
- GeneNews
- NanoRepro AG
- Nantong Egens Biotechnology
- Orion Diagnostica
- Polymedco
- Quest Diagnostics
- Randox
- VolitionRx.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll